HUTCHMED (HCM) Competitors

HUTCHMED (NASDAQ:HCM) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Does the media favor HCM or ARWR?

In the previous week, HUTCHMED and HUTCHMED both had 2 articles in the media. HUTCHMED's average media sentiment score of 0.91 beat Arrowhead Pharmaceuticals' score of 0.44 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is HCM or ARWR more profitable?

HUTCHMED has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -163.32%. HUTCHMED's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-163.32%	-90.77%	-38.56%

Does the MarketBeat Community prefer HCM or ARWR?

Arrowhead Pharmaceuticals received 209 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.74% of users gave HUTCHMED an outperform vote while only 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
HUTCHMED	Outperform Votes 313 66.74%	Underperform Votes 156 33.26%
Arrowhead Pharmaceuticals	Outperform Votes 522 65.25%	Underperform Votes 278 34.75%

Which has stronger valuation & earnings, HCM or ARWR?

HUTCHMED has higher revenue and earnings than Arrowhead Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$838M	3.43	$100.78M	N/A	N/A
Arrowhead Pharmaceuticals	$240.74M	11.49	-$205.27M	-$2.78	-8.03

Do analysts recommend HCM or ARWR?

HUTCHMED presently has a consensus price target of $29.70, suggesting a potential upside of 80.00%. Arrowhead Pharmaceuticals has a consensus price target of $53.45, suggesting a potential upside of 139.38%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Do institutionals & insiders believe in HCM or ARWR?

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more volatility & risk, HCM or ARWR?

HUTCHMED has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

HUTCHMED beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.